Tredje AP fonden Grows Position in Stryker Corporation $SYK

Tredje AP fonden boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 32.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 131,561 shares of the medical technology company’s stock after purchasing an additional 31,861 shares during the period. Tredje AP fonden’s holdings in Stryker were worth $46,240,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. United Financial Planning Group LLC purchased a new position in Stryker during the third quarter valued at $27,000. CGC Financial Services LLC purchased a new position in Stryker during the fourth quarter valued at $29,000. Strive Asset Management LLC purchased a new position in Stryker during the third quarter valued at $30,000. ANTIPODES PARTNERS Ltd purchased a new position in Stryker during the third quarter valued at $34,000. Finally, Copia Wealth Management lifted its position in Stryker by 181.6% during the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of Stryker stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.60% of the stock is owned by insiders.

Stryker Price Performance

Shares of Stryker stock opened at $312.99 on Tuesday. The stock’s 50-day simple moving average is $328.54 and its 200-day simple moving average is $351.06. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The company has a market capitalization of $119.99 billion, a price-to-earnings ratio of 36.23, a PEG ratio of 1.93 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the firm earned $2.84 earnings per share. Stryker’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is presently 40.74%.

Analyst Upgrades and Downgrades

SYK has been the topic of several analyst reports. Wells Fargo & Company lowered their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. JPMorgan Chase & Co. lowered their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.